Clinical Trials Browser

Pathologic Complete Response × Thoracic × Clear all

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06743555 2024-12-20

SAVED LUNG

Phase 1 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT05925751 2023-06-29

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis